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Abstract: BACKGROUND: The use of alkylating chemotherapy versus bevacizumab for recurrent glioblas-
toma remains controversial. Here, we tested the hypothesis that the activity of alkylators, but not that
of bevacizumab, would be associated with the O6-methylguanine DNA methyltransferase (MGMT) pro-
moter methylation status. METHODS: We analyzed a cohort of patients treated at centers of the German
Glioma Network or the University Hospital Zurich with alkylating agent-based chemotherapy (n = 260)
or bevacizumab without or with irinotecan (n = 84) for first recurrence of glioblastoma. Outcome was
stratified for O6-methylguanine DNA methyltransferase (MGMT) status and crossover to bevacizumab
or alkylators at further progression. RESULTS: Median post-recurrence survival-1 (PRS-1) for patients
receiving alkylating agents at first recurrence was longer than with bevacizumab (11.1 versus 7.4 months,
p < 0.001). The use of alkylators was associated with longer PRS-1 for patients with a methylated
versus unmethylated MGMT promoter (p = 0.017). For patients receiving bevacizumab, PRS-1 was not
different with or without MGMT promoter methylation. PRS-1 was longer in patients receiving alkylat-
ing chemotherapy compared to bevacizumab for patients with methylated (p < 0.001) or unmethylated
MGMT promoter (p = 0.034). For patients with alkylators at first recurrence receiving bevacizumab
at any further recurrence, PRS-1 was longer than in patients receiving bevacizumab first and alkylators
thereafter (p = 0.002). CONCLUSIONS: This study confirms limited value of bevacizumab in recurrent
glioblastoma independent of MGMT status. Alkylating agents have activity in recurrent glioblastoma,
especially in the context of MGMT promoter methylation.
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The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains 
controversial. Here we tested the hypothesis that the activity of alkylators, but not that of 
bevacizumab, would be associated with the O6-methylguanine DNA methyltransferase (MGMT) 
promoter methylation status. 
Methods:  
We analyzed a cohort of patients treated at centers of the German Glioma Network or the University 
Hospital Zurich with alkylating agent-based chemotherapy (n=260) or bevacizumab without or with 
irinotecan (n=84) for first recurrence of glioblastoma. Outcome was stratified for O6-methylguanine 
DNA methyltransferase (MGMT) status and cross-over to bevacizumab or alkylators at further 
progression. 
Results:  
Median post-recurrence survival-1 (PRS-1) for patients receiving alkylating agents at first recurrence 
was longer than with bevacizumab (11.1 versus 7.4 months, p<0.001). The use of alkylators was 
associated with longer PRS-1 for patients with a methylated versus unmethylated MGMT promoter 
(p=0.017). For patients receiving bevacizumab, PRS-1 was not different with or without MGMT 
promoter methylation. PRS-1 was longer in patients receiving alkylating chemotherapy compared to 
bevacizumab for patients with methylated (p<0.001) or unmethylated MGMT promoter (p=0.034). For 
patients with alkylators at first recurrence receiving bevacizumab at any further recurrence, PRS-1 
was longer than in patients receiving bevacizumab first and alkylators thereafter (p=0.002). 
Conclusions:  
This study confirms limited value of bevacizumab in recurrent glioblastoma independent of MGMT 







Glioblastoma exhibits a poor prognosis despite multimodal therapy consisting of surgery followed by 
temozolomide (TMZ)-based radiochemotherapy. The concept of radiotherapy combined with 
concomitant and maintenance TMZ as the standard of care was introduced 2005 based on a phase III 
trial of the European Organisation for Research and Treatment of Cancer (EORTC) / National Cancer 
Institute of Canada Clinical Trials Group (NCIC-CTG) (Stupp et al. 2005). In parallel, promoter 
methylation of the DNA repair gene O6-methylguanine DNA methyltransferase (MGMT) was 
established as a predictive biomarker for benefit from chemotherapy with TMZ (Hegi et al. 2005). In 
the pre-TMZ era, population-based overall survival (OS) was 4.9 months (1980-1994) in one study 
(Ohgaki et al. 2004), and 8.1 months (2000-2003) in another study (Johnson and O'Neill 2012). After 
the introduction of TMZ in 2005, OS was 9.7 months for the period of 2005 to 2008 in a US study 
(Johnson and O'Neill 2012) and 11 months between 2005 and 2009 in the Canton of Zurich, 
Switzerland (Gramatzki et al. 2016). This might be explained at least in part by the increasing use of 
various, albeit modestly effective therapeutic options at recurrence. Alkylating chemotherapy with TMZ 
or nitrosoureas (e.g. lomustine, carmustine, fotemustine) and bevacizumab are the agents used most 
frequently in recurrent glioblastoma. The DIRECTOR trial which compared two different dose-intense 
TMZ schedules at first recurrence indicated that benefit of TMZ may be restricted to patients with 
tumors with MGMT promoter methylation (Weller et al. 2015). 
Bevacizumab was conditionally approved in 2009 in the US and in several other countries based on 
promising radiographic response rates in 2 phase II trials in patients with recurrent glioblastoma 
(Friedman et al. 2009; Kreisl et al. 2009). The BELOB phase II trial randomized patients to either 
bevacizumab or lomustine monotherapy or the combination of both (Taal et al. 2014). Median OS in 
both monotherapy arms was 8 months, but 12 months for the combination. Yet, an OS benefit for the 
combination compared to lomustine monotherapy was not confirmed in the ensuing EORTC 26101 
phase III trial (Wick et al. 2017). Yet, given the poor performance of dose-dense TMZ in the 
DIRECTOR trial in patients with MGMT promoter-unmethylated tumors (Weller et al. 2015), we 
hypothesized that bevacizumab might be a preferable option specifically in this cohort of patients with 
recurrent glioblastoma. The aim of the current study was thus to evaluate the outcome of patients with 
glioblastoma who received either alkylating agents (TMZ or nitrosoureas) or bevacizumab at first 
recurrence with respect to MGMT promoter methylation status and further treatment at second or later 
recurrences. 
 





We reviewed clinical data of patients who received the alkylating agents TMZ or a nitrosourea-based 
regimen (lomustine, carmustine or nimustine) as monotherapy or in combination with other 
chemotherapeutic agents including procarbazine, procarbazine plus vincristine, teniposide, etoposide 
or blinded cediranib/placebo) or bevacizumab for first recurrence of glioblastoma and who had 
information on the MGMT promoter methylation status of the initial tumor available. Patients treated 
with a combination of bevacizumab and irinotecan at first recurrence were included but patients who 
received bevacizumab with any other combination therapy were excluded, including patients who 
received a combination of alkylators and bevacizumab. The patient cohort consisted of patients 
treated at centers of the German Glioma Network (GGN), a prospective noninterventional cohort 
involving eight clinical centers in Germany (www.gliomnetzwerk.de) and of patients, retrospectively 
analyzed, treated at the University Hospital Zurich, Switzerland. Data for a subset of 41 patients 
treated at the University Hospital Zurich have been included in a previous publication (Gramatzki et al. 
2018). This study was approved by the responsible review committees of the participating centers of 
the German Glioma Network in Germany (353/2003V) and the University Hospital Zurich, Switzerland 
(2015-0437). There was no central radiological review for tumor progression. Depending of the 
respective time of progression either Macdonald criteria (Macdonald et al. 1990) (before 2010) or 
RANO criteria (Wen et al. 2010) (after their publication in 2010) were applied locally at the sites. The 
methylation status of the MGMT promoter was assessed according to local standards using either 
methylation-specific PCR or pyrosequencing. Isocitrate dehydrogenase (IDH)1 or IDH2 mutation 
status was tested by local standards; it was available for 243 patients: 74 tumors were evaluated by 
immunohistochemistry for IDH1R132H, 154 tumors by IDH1/2 sequencing and 3 tumors by 450K DNA 
methylation profiling. For 12 patients the method could not be specified during the clinical chart review. 
Progression-free survival after initial diagnosis of glioblastoma (PFS-1) was calculated from primary 
surgery to tumor progression, and OS from primary surgery to death or last follow-up. PFS-2 was 
calculated for the subgroup of patients receiving systemic therapy for second recurrence and defined 
as the period from the first day of systemic treatment for first recurrence to the date of initiation of any 
therapeutic intervention for second recurrence. Post-recurrence survival-1 (PRS-1) was calculated 
from the first day of systemic treatment for recurrent disease to death or the date of last contact. PRS-
2 was calculated in the subgroup of patients receiving systemic treatment for second recurrence from 
the first day of medical treatment for second relapse to death or the date of last contact. Patients were 
censored at last follow-up. Patient age data are described by median and range. For categorical data 
absolute and relative frequencies are given. Patient characteristics for groups A versus B were 
compared by Chi-square-test, Fisher’s Exact test and Student’s t-test. Survival data were analyzed by 
log-rank-test and are presented as Kaplan-Meier curves. Cox regression analyses were used to 
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assess the association of chemotherapy with PRS-1 adjusted for age, first-line therapy, extent of initial 





We identified a total of 344 patients treated either with alkylating chemotherapy (Group A, n=260 total, 
n=168 with TMZ, n=92 with a nitrosourea-based regimen as specified in Table 1) or bevacizumab 
(Group B, n=84 total, n=66 with bevacizumab alone, n=18 for bevacizumab in combination with 
irinotecan) for the first recurrence of glioblastoma. Details on demographic and clinical characteristics 
are summarized in Table 1. Age, gender, differences in first-line therapy and extent of surgery at first 
recurrence were well balanced between both groups while significant differences were seen regarding 
the extent of initial surgery (p=0.006), PFS-1 (p<0.001), Karnofsky performance status (KPS) 
(p=0.007), MGMT promoter methylation status (p<0.001) and IDH mutation status (p=0.006). In group 
A, 138 patients (53.1%), in group B, 20 patients (23.8%) had tumors with MGMT promoter 
methylation. IDH testing was available for 192 patients (74%) in group A: it was mutant in 23 of these 
patients (12%). In group B, for 51 patients (61%) IDH testing was available which was uniformly wild-
type. To account for this imbalance in patient characteristics, we performed separate analyses of the 
cohort of patients with known IDH status and excluded patients with IDH-mutant tumors (Table S1).  
 
Outcome 
Three hundred seven of 344 patients of the entire cohort died. Median follow-up of surviving patients 
was 22.1 months. PRS-1 was longer for patients receiving alkylating agent chemotherapy than for 
patients receiving bevacizumab (Fig. 1A, p<0.001). This was similar for the subgroup of patients with 
known IDH status and exclusion of patients with IDH-mutant tumors (Fig. 1B, p=0.001). Surgery for 
recurrence was not prognostic for PRS-1 (HR=0.95, p=0.698). We noted that there were differences in 
prognostic factors between both cohorts (Table 1) likely related to physicians` choices of the first 
salvage therapy. PFS-1 had been longer for patients placed on alkylating agents at first recurrence 
compared to bevacizumab (Fig. 1C for the entire cohort, Fig. 1D for the subgroup of patients with 
known IDH status and exclusion of patients with IDH-mutant tumors), as was OS from initial diagnosis 
in these cohorts (p<0.001) (Fig. 1E,F). Median PFS-1 was 8.7 months (95% CI 6.9-10.5) and PRS-1 
was 11.1 months (95% CI 10.2-12.1) for patients receiving alkylating agent chemotherapy at first 
recurrence as opposed to 6.1 months (95% CI 5.2-7.1) and 7.4 (95% CI 5.7-9.0) for patients treated 
with bevacizumab (Fig. 1G). For the subgroup of patients with known IDH status and exclusion of 
patients with IDH-mutant tumors, median PFS-1 was 8.7 months (95% CI 6.3-11.1) and median PRS-
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1 was 11.1 months (95% CI 9.9-12.3) for patients receiving alkylating agent chemotherapy as 
opposed to 6.9 months (95% CI 5.3-8.5) and 7.1 months (95% CI 5.2-9.1) for patients receiving 
bevacizumab at first recurrence (Fig. 1H). We performed subgroup analyses for the patients receiving 
alkylating agents regarding differences in PFS-1 or OS when stratified by use of TMZ or nitrosoureas. 
Both PFS-1 and OS were longer for patients receiving TMZ versus nitrosoureas for first recurrence 
(p=0.003 and p=0.04) for the entire patient cohort. For the subcohort of patients with known IDH status 
and after exclusion of patients with IDH-mutant tumors, PFS-1 was still longer for patients receiving 
TMZ versus nitrosoureas (p=0.005) while no difference was seen for OS (p=0.164). 
 
MGMT promoter methylation status and outcome 
Next, we stratified the patient cohorts with respect to MGMT promoter methylation status. PRS-1 for 
patients receiving alkylating agent chemotherapy at first recurrence was longer for patients with 
MGMT promoter-methylated tumors than for unmethylated tumors (Fig. 2A, p=0.017). For the patients 
receiving bevacizumab, PRS-1 was not different by MGMT promoter methylation status. PRS-1 was 
longer in the group receiving alkylating chemotherapy than in the group with bevacizumab both for 
patients with tumors with methylated or with unmethylated MGMT promoter (p<0.001 and p=0.034). 
For the subgroup of patients with known IDH status and exclusion of patients with IDH-mutant tumors, 
there was only a trend towards a PRS-1 difference for patients receiving alkylating chemotherapy with 
methylated versus unmethylated MGMT promoter (Fig. 2B, p=0.15). For the comparison of patients 
receiving alkylating chemotherapy versus bevacizumab, longer PRS-1 was only seen in patients with 
MGMT promoter-methylated tumors (p<0.001), while there was no difference if difference in patients 
with MGMT promoter-unmethylated tumors (p=0.12) (Fig. 2B). As above, we also looked at the overall 
disease trajectory in these patient groups. PFS-1 and OS were longer in patients receiving alkylating 
agents versus bevacizumab at first progression both in case of a methylated MGMT promoter 
(p=0.004 and p<0.001) and in case of an unmethylated MGMT promoter (p=0.014 and p=0.001) (Fig. 
2C,E). For the subgroup excluding patients with IDH-mutant tumors, there was no significant 
difference for PFS-1 both with and without MGMT promoter methylation (p=0.11 and p=0.14), while 
OS was longer both with and without MGMT promoter methylation (p<0.001 and p=0.026) for patients 
receiving alkylators than for patients receiving bevacizumab (Fig. 2D,F). Patients receiving alkylating 
agents at first progression had longer PFS-1 and OS when their tumors carried a methylated MGMT 
promoter (p<0.001 and p<0.001 for the entire patient cohort, Fig. 2C,E; p<0.001 and p=0.001 for the 
subgroup with known IDH status and after exclusion of patients with IDH-mutant tumors, Fig. 2D,F). 
Median PFS-1 in the patient group treated with alkylating agents was 15.0 months (95% CI 11.0-18.9) 
for patients with MGMT promoter-methylated tumors and 6.5 months (95% CI 5.5-7.4) for patients with 
MGMT promoter-unmethylated tumors, as well as 8.7 months (95% CI 7.6-9.9) and 5.6 months (95% 
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CI 5.0-6.3) for patients receiving bevacizumab stratified according to methylated and unmethylated 
MGMT promoter status. Median PRS-1 in the group treated with alkylating agents was 12.2 months 
(95% CI 10.1-14.3) for MGMT promoter-methylated and 8.7 months (95% CI 7.0-10.3) for MGMT 
promoter-unmethylated glioblastoma patients, and in the group receiving bevacizumab 8.2 months 
(95% CI 3.8-12.6, MGMT promoter methylated) and 7.3 months (95% CI 6.0-8.7, MGMT promoter 
unmethylated), respectively (Fig. 2G). Median PFS-1 and median PRS-1 with stratification for MGMT 
status for the subgroup with exclusion of IDH-mutant tumors are shown in Fig. 2H. 
 
Further salvage therapies and outcome 
Differences in PRS may also depend on subsequent salvage therapies. Details regarding the different 
salvage therapies for second or later recurrences are shown in Table S2. PRS-1 for patients with 
alkylating chemotherapy at first recurrence who received bevacizumab at any further recurrence was 
longer than for patients receiving bevacizumab at first recurrence and alkylating chemotherapy 
salvage therapy at any further progression (Fig. 3A for the entire cohort, p=0.002, Fig. 3B for the 
subgroup with known IDH status and excluding IDH-mutant tumors, p<0.001). PRS-1 for patients that 
received alkylating chemotherapy at first recurrence and no bevacizumab at any further recurrence 
was longer than in patients receiving bevacizumab at first recurrence and no alkylating chemotherapy 
as salvage therapy at any further progression (Fig. 3A for the entire cohort, p<0.001, Fig. 3B for the 
subgroup excluding IDH-mutant tumors, p=0.001). PFS-1 and OS stratified for differences in further 
salvage therapy were significantly longer when comparing the patient groups receiving alkylating 
agents at first recurrence followed by a bevacizumab-containing regimen versus those receiving 
bevacizumab first and alkylating agents thereafter (p<0.001 for PFS-1, p<0.001 for OS). Further, PFS-
1 and OS were longer for patients receiving alkylating agents first and thereafter no bevacizumab 
versus receiving bevacizumab first and no alkylating agents thereafter (p<0.001 for PFS-1, p<0.001 
for OS) (Fig. 3C,E). For the subgroup of patients with exclusion of patients with IDH-mutant tumors, 
differences in PFS-1 and OS comparing these patient groups were similar, with the exception that 
there was no significant difference in PFS-1 when comparing patients receiving alkylating agents first 
and no bevacizumab thereafter with patients receiving bevacizumab first and no alkylating agents 
thereafter (p=0.055) (Fig. 3D,F). Median PFS-1 and median PRS-1 are shown in Fig. 3G for the entire 
patient cohort and Fig. 3H for the subgroup excluding IDH-mutant tumors, 95%-confidence intervals 
for these outcome parameters are summarized in Table S3. For those patients receiving further 
systemic salvage therapy for second recurrence (n=183 for the entire cohort and n=113 for the cohort 
with known IDH status and exclusion of patients with IDH-mutant tumors), we assessed the median 
time from initiation of systemic treatment for first recurrence until the initiation of any salvage therapy 
for second recurrence (“PFS-2”) and survival from initiation of systemic treatment for second 
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recurrence to death or the date of last contact (“PRS-2”) (Fig. 3 IJ). Statistical analyses were omitted 
for the patient group with bevacizumab at first recurrence receiving any other systemic salvage 
therapy but no alkylators at second recurrence due to low patient numbers (n=5 for the entire cohort 
and n=2 for the subgroup with exclusion of patients with IDH-mutant tumors). There was no difference 
in PFS-2 but longer PRS-1 (p=0.002) and PRS-2 (p<0.001) when comparing patients receiving 
alkylating chemotherapy first and a bevacizumab-containing regimen thereafter (n=74) versus 
bevacizumab first and alkylators thereafter (n=39). PFS-2 was shorter (p=0.033) while PRS-1 and 
PRS-2 were not different for patients with alkylating agents first and bevacizumab for second or later 
salvage therapy versus any other salvage therapy but no bevacizumab (n=65). For the subgroup with 
known IDH status and exclusion of patients with IDH-mutant tumors, similarly, PFS-2 was not 
different, PRS-1 (p<0.001) and PRS-2 (p<0.001) were longer when comparing patients receiving 
alkylating chemotherapy first and a bevacizumab-containing regimen thereafter (n=46) versus 
bevacizumab first and alkylators thereafter (n=26). In this subcohort, PFS-2, PRS-1 and PRS-2 were 
not different for patients with alkylating agents first and bevacizumab thereafter versus any other 
salvage therapy but no bevacizumab for second or later salvage therapy (n=39). 
 
Multivariate analyses 
We performed multivariate Cox regression analyses (Table 2) to account for differences in potential 
prognostic factors for PRS-1 in patients treated with alkylating agents versus bevacizumab-containing 
regimens at first recurrence. We started with a model including all patients with available 
documentation (n=317) on age, MGMT promoter methylation, first-line therapy and extent of initial 
surgical resection (model 1). PRS-1 was superior in patients receiving alkylating agents versus 
bevacizumab for first recurrence (hazard ratio (HR)=0.59, 95% CI 0.44-0.78, p<0.001). Age and 
MGMT promoter methylation had significant prognostic relevance. KPS as a known prognostic factor 
for newly diagnosed glioblastoma was omitted for this analysis since no prognostic role was 
determined in the DIRECTOR trial evaluating two different regimens of TMZ for recurrent glioblastoma 
(Weller et al. 2015) and data for KPS at recurrence were only available for a subset of patients (229 of 
317). Next, we analyzed a Cox regression model for PRS-1 comparing patients with alkylating 
chemotherapy at first recurrence receiving bevacizumab thereafter versus bevacizumab first and 
alkylating agents at any further recurrence as well as comparing the group with alkylating agents first 
and no bevacizumab at further recurrence versus bevacizumab first and no alkylators thereafter 
(model 2). In this model, the difference in PRS-1 in patients receiving alkylating agents at first 
recurrence and bevacizumab thereafter compared to patients with bevacizumab first and alkylating 
agents thereafter was not significant (HR=0.66, 95% CI 0.42-1.02, p=0.063). Furthermore, this model 
confirmed superior PRS-1 in patients with alkylators first and no bevacizumab at further recurrence 
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compared to bevacizumab first and no alkylators thereafter (HR=0.46, 95% CI 0.32-0.66, p<0.001). 
Similar to model 1, MGMT promoter methylation and age were of significant prognostic relevance for 
PRS-1. We also performed the multivariate analyses of models 1 and 2 for the subcohort of patients 
with known IDH status and exclusion of patients with IDH-mutant tumors (Table S4, n=206). In model 
1, prognostic significance for PRS-1 for patients receiving alkylating agents versus bevacizumab at 
first recurrence was confirmed with a HR of 0.57 (95% CI 0.39-0.83, p=0.003) while MGMT status and 
age were not prognostic. In model 2, PRS-1 was superior for patients receiving alkylating agents at 
first recurrence both for the comparison of alkylators first and bevacizumab at any further recurrence 
with bevacizumab first and alkylating agents thereafter (HR=0.54, 95% CI 0.31-0.94, p=0.03) and for 
the comparison of alkylating agents first and no bevacizumab at further recurrence with bevacizumab 
first and no alkylators thereafter (HR=0.48, 95% CI 0.30-0.77, p=0.003). Comparable to model 1 for 




This study explored the outcome of patients with glioblastoma treated with either alkylating 
chemotherapy or bevacizumab at first recurrence, stratified for MGMT promoter methylation status 
and further salvage treatment. Worldwide, there is no consensus for standard of care for patients with 
glioblastoma at first recurrence. With respect to medical therapy, bevacizumab is approved for 
treatment of recurrent glioblastoma in the US and some other countries, but not in the European 
Union. In Europe, treatment with alkylating agents is a widely accepted regimen for patients with 
recurrent glioblastoma (Weller et al. 2017) not only, but also because the access to bevacizumab is 
limited. Accordingly, lomustine was chosen as a comparator for experimental agents in several 
randomized phase III trials (Batchelor et al. 2013; Wick et al. 2017; Wick et al. 2010). The choice of 
either alkylating chemotherapy or bevacizumab for treatment at recurrence of glioblastoma may also 
depend on MGMT promoter methylation status since the DIRECTOR trial showed a much more 
favorable outcome of patients with MGMT promoter-methylated tumors treated with TMZ compared to 
patients with MGMT promoter-unmethylated tumors (Weller et al. 2015). Although the EORTC 26101 
phase III trial showed no OS benefit for the combination of bevacizumab and lomustine versus 
lomustine alone (Wick et al. 2017), the prolongation of progression-free survival with bevacizumab 
may be considered beneficial, especially in the context of a tumor-related symptom burden. In 
summary, the question of whether alkylating chemotherapy or bevacizumab should be the preferred 
treatment option at first recurrence remains controversial. 
Our analysis supports the choice of alkylating chemotherapy at first recurrence and postponing 
treatment with bevacizumab since PRS-1 was longer for patients receiving alkylating chemotherapy 
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compared with bevacizumab at first recurrence (Fig. 1A,B), with a HR of 0.59 in multivariate analysis 
(Table 2). We acknowledge that differences in prognostic factors may contribute to the reported 
outcome data since MGMT promoter methylation and age were significant prognostic cofactors for 
PRS-1 on multivariate analysis (Table 2). 
Notably, PRS-1 of patients receiving alkylating chemotherapy was longer than in patients receiving 
bevacizumab independent of the MGMT promoter methylation status (Fig. 2). Given the poor outcome 
for patients with MGMT promoter-unmethylated tumors and the lack of a difference in PRS-1 between 
the patient groups receiving either bevacizumab or alkylating agents in the subcohort with known IDH-
status and exclusion of patients with IDH-mutant tumors, the use of any salvage therapy in patients 
with an MGMT promoter-unmethylated glioblastoma is questionable. So far, there are no data 
comparing alkylating agents or bevacizumab versus best supportive care especially in the group of 
patients with MGMT promoter-unmethylated glioblastoma. Data of the BELOB phase II trial, 
suggested longer OS in patients with recurrent glioblastoma with MGMT promoter methylation 
receiving bevacizumab rather than lomustine (Taal et al. 2014). However, this was not confirmed in 
the EORTC 26101 phase III trial showing a prognostic role of MGMT promoter methylation 
independent of whether patients were treated with lomustine plus bevacizumab or bevacizumab alone 
(Wick et al. 2017). Conclusions regarding the value of MGMT status and the efficacy of lomustine, 
however, are limited since there is no lomustine-free treatment arm in this trial. In summary, we 
conclude that the use of bevacizumab is not supported by presence versus absence of MGMT 
promoter methylation while the use of alkylating chemotherapy may be beneficial in patients with 
recurrent glioblastoma and a methylated MGMT promoter.  
Regarding the role of further salvage therapy after treatment with either alkylating agents or 
bevacizumab for first recurrence, we found longer PRS-1 and PRS-2 when alkylators were used first 
and bevacizumab thereafter in contrast to the use of bevacizumab first and alkylating agents 
thereafter (Fig. 3). We acknowledge that interpretation of these data is limited by potential selection 
bias of the treating physicians, differences in prognostic factors and heterogeneity of salvage 
therapies including the fact that patients were grouped for receiving alkylators or bevacizumab at any 
further recurrence without further stratification for the number of recurrences which would have further 
limited sample sizes of the respective subgroups. However, the more favorable outcome for patients 
receiving alkylators versus bevacizumab for first recurrence was confirmed on multivariate analyses 
with MGMT promoter methylation and age as prognostic cofactors (Table 2 and S4, model 1). Still, in 
the multivariate analyses regarding the different crossover regimens, PRS-1 was superior for the 
group of patients with alkylators first and a bevacizumab-containing regimen thereafter compared with 
bevacizumab first and alkylators thereafter was only confirmed for the subgroup with known IDH-
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status and exclusion of IDH-mutant patients and not for the entire patient cohort (Table 2 and S4, 
model 2). 
The observation that the early use of bevacizumab for recurrent glioblastoma might not be beneficial is 
supported by an epidemiologic study showing that PRS of patients receiving no bevacizumab at first 
recurrence was longer than in patients that received the drug as first choice for recurrent disease 
(Gramatzki et al. 2018). A retrospective series of 298 patients with recurrent glioblastoma did not find 
significant differences for the median time to further tumor progression after initiation of bevacizumab 
between patients with early versus delayed administration of bevacizumab while median OS was 
longer in patients with delayed administration of bevacizumab (Hamza et al. 2014). The benefit in OS 
in the latter study may be interpreted by selection bias and prognostic factors but also may point 
towards a benefit of other therapies including alkylators applied early for recurrent glioblastoma. 
Another retrospective study with 468 patients receiving bevacizumab for different recurrences of 
glioblastoma similarly did not find significant differences, neither with regard to the time to further 
tumor progression nor to the survival time after initiation of bevacizumab (Piccioni et al. 2014). The 
EORTC 26101 trial had initially started as a phase II trial including treatment arms of bevacizumab 
and lomustine monotherapy with the possibility of crossover at further recurrence. The results of the 
early phase of this trial as published at ASCO 2016 indicated similar median OS for the different 
treatment groups (Wick et al. 2016). However, the final results may add further evidence to decide on 
the sequence of either alkylating chemotherapy or bevacizumab in treatment of recurrent 
glioblastoma. 
Given the poor outcome for patients treated with bevacizumab in our cohort and in the studies 
discussed above (Gramatzki et al. 2018; Hamza et al. 2014; Wick et al. 2017), its use for patients with 
recurrent glioblastoma remains questionable. Symptom control remains one of the main indications. In 
the context of reirradiation, reduced radiation-associated toxicity has been reported with regard to 
symptomatic radionecrosis and symptomatic edema when patients are co-exposed to bevacizumab 
(Fleischmann et al. 2019). However, the value of reirradiation alone or in combination bevacizumab for 
patients with recurrent glioblastoma remains controversial due to the lack of prospective randomized 
studies. One retrospective study with 71 patients indicated some potential benefit for PFS and OS 
(Flieger et al. 2014) while another retrospective analysis of a small cohort with 14 patients reported 
higher PFS but shorter OS for patients with recurrent “high-grade” glioma treated by reirradiation with 
and without bevacizumab (Hundsberger et al. 2013). Prospective evaluation of combined reirradiation 
and bevacizumab was done in a phase-1 trial with a total of 15 patients with a dose escalation up to 
3x11 Gy reporting a median overall survival of 13 months (Clarke et al. 2017). 
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Beyond the limitations of our study that have already been discussed, we also acknowledge that the 
retrospective character of analysis limits data interpretation also with regard to the heterogeneity of 
patient cohorts and small patient numbers in subgroups. 
In conclusion, this study confirms that the value of bevacizumab in recurrent glioblastoma is limited 
with regard to survival and that outcome is independent of the MGMT status. Alkylating agents such 
as TMZ and lomustine have activity in patients with recurrent glioblastoma, mainly in the context of a 






Fig. 1. Outcome stratified for treatment at first recurrence. Outcome for the entire patient cohort 
(left) or the subgroup of patients with known IDH status and exclusion of patients with IDH-mutant 
tumors (right) treated with alkylating agents (blue curve) or bevacizumab alone or in combination with 
irinotecan (red curve) at first recurrence: Post-recurrence survival-1 (PRS-1) (A,B), progression-free 
survival from initial diagnosis (PFS-1) (C,D), overall survival (OS) from initial diagnosis (E, F), and 
median PFS-1 and median PRS-1 (G,H) 
 
Fig. 2. Outcome stratified by treatment and MGMT status. Outcome data for the entire patient 
cohort (left) or the subgroup of patients with known IDH status and exclusion of patients with IDH-
mutant tumors (right) treated at first recurrence with either alkylating agents (blue curves) or 
bevacizumab (red curves) stratified for methylated (continuous line) or unmethylated (dashed line) 
MGMT promoter: post-recurrence survival-1 (PRS-1) (A,B), progression-free survival from initial 
diagnosis (PFS-1) (C,D), overall survival (OS) from initial diagnosis (E,F), and median PFS-1 and 
median PRS-1 (G,H). 
 
Fig. 3. Outcome stratified for further salvage therapies. Outcome data for the entire patient cohort 
(left) or the subgroup of patients with known IDH status and exclusion of patients with IDH-mutant 
tumors (right) treated at first recurrence with alkylating agents followed by a bevacizumab-containing 
regimen at any further recurrence (blue continuous line) or never received bevacizumab at any further 
salvage therapy (blue dashed line) or treated with a bevacizumab-containing regimen at first 
recurrence followed by treatment with alkylators at any further recurrence (red continuous line) or 
never receiving alkylators at any further salvage therapy (red dashed curve): post-recurrence survival-
1 (PRS-1) (A,B), progression-free survival from initial diagnosis (PFS-1) (C,D), overall survival (OS) 
from initial diagnosis (E,F), median PFS-1 and median PRS-1 (G,H). In the subgroup of patients 
receiving further systemic therapy after second recurrence, median PFS-1, median time from initiation 
of systemic treatment for first recurrence until the initiation of any salvage therapy for second 
recurrence (PFS-2) and survival from systemic treatment for second recurrence to death (PRS-2) was 
also assessed (I,J). 
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Table 1: Patient characteristics for the entire cohort 
Therapy for first recurrence Alkylating agent-based 
chemotherapy (Group A, 
n=260)1 
Bevacizumab 
(Group B, n=84)2 
p value 
Age at diagnosis (years)    
 Median (Range) 58 (24-80) 55 (25-79) 0.341 
Gender    
 Male 157 (60.4%) 53 (63.1%) 0.658 
 Female 103 (39.6%) 31 (36.9%)  
Initial surgery    
 Gross total resection 115 (48.9%) 23 (28.0%) 0.006 
 Subtotal resection (50-99%) 80 (34.0%) 34 (41.5%)  
 Partial resection (<50%) 24 (10.2%) 14 (17.1%)  
 Biopsy 16 (6.8%) 11 (13.4%)  
 No data 25 2  
First-line therapy    
 Radiotherapy alone 44 (16.9%) 11 (13.1%) 0.517 
 Radiotherapy plus TMZ 200 (76.9%) 70 (83.3%)  
 Radiotherapy plus others3 6 (2.3%) 0 (0%)  
 Radiotherapy plus TMZ plus 
 others3 
10 (3.8%) 3 (3.6%)  
PFS-1 (months)    
 Median (95% CI) 8.7 (6.9-10.5) 6.1 (5.2-7.1) <0.001 
Karnofsky performance score at 
recurrence 
   
 90-100 70 (38.5%) 17 (27.4%) 0.007 
 70-80 86 (47.3%) 25 (40.3%)  
 <70 26 (14.3%) 20 (32.3%)  
Not available 78 22  
Surgery at first recurrence 100/260 (38.5%) 13/84 (15.5%)  
 Gross total resection  44 (51.8%)  2 (20.0%) 0.183 
 Subtotal resection (50-99%)  33 (38.8%)  7 (70.0 %)  
 Partial resection (<50%)  8 (9.4 %)  1 (10.0%)  
 Extent of resection unknown  15  3   
MGMT promoter methylation 
status 
   
 Methylated 138 (53.1%) 20 (23.8%) <0.001 
 Unmethylated 122 (46.9%) 64 (76.2%)  
IDH1/2  mutation status    
Mutated 23 (12.0%) 0 (0%) 0.006 
Not mutated 169 (88.0%) 51 (100%)  
Unknown 68 33  
1168 patients received TMZ, 92 patients received a nitrosourea-based regimen with monotherapy with 
lomustine (n=23), carmustine (n=15) or nimustine (n=9), or combination regimens with procarbazine, 
lomustine and vincristine (n=15), procabazine and lomustine (n=1), nimustine plus teniposide (n=12), 
carmustine plus teniposide (n=9), lomustine plus etoposide (n=7), lomustine plus cediranib or placebo 
(blinded, n=1) 
218 patients received irinotecan in addition 
3Other therapies applied were tumor-treating fields, cilengitide, enzastaurin, cetuximab, temsirolimus, 
galunisertib, proton beam therapy, gene therapy 
 
Table 2: Multivariate analysis for survival after first recurrence (PRS-1) 
Model Factor HR 95% CI p value 
1 
(n=317) 
Therapy at recurrence: 
Alkylating agents versus bevacizumab (ref) 
0.59 0.44-0.78 <0.001 
 MGMT: 
Methylated versus unmethylated (ref) 
0.75 0.59-0.97 0.027 
 Age (years) 
≤65 versus >65 (ref) 
0.66 0.49-0.87 0.004 
 Firstline therapy 
Radiotherapy plus TMZ +/- others versus 
radiotherapy +/- others (ref) 
0.99 0.73-1.36 0.970 
 Extent of initial surgery: 
Gross total versus no total (ref) 
0.90 0.71-1.14 0.373 
     
2 
(n=317) 
Therapy at recurrence: 
Alkylating agents  bevacizumab versus 
Bevacizumab  alkylating agents (ref) 
 
Alkylating agents  no bevacizumab versus 
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Table S1: Patient characteristics for the subgroup with known IDH status 
excluding patients with IDH-mutant tumors 
Therapy for first recurrence Alkylating agent-
based 
chemotherapy 
(Group A), n=169 
Bevacizumab 
with or without 
irinotecan  
(Group B), n=51 
p-value 
Age at diagnosis (years)    
 Median (Range) 58 (29-80) 56 (29-79) 0.490 
    
Gender    
 Male 97 (57.4%) 33 (64.7%) 0.352 
 Female 72 (42.6%) 18 (35.3%)  
Initial surgery    
 Gross total resection 80 (51.3%) 15 (30.0%) 0.025 
 Subtotal resection (50-99%) 55 (35.3%) 21 (42.0%)  
 Partial resection (<50%) 12 (7.7%) 8 (16.0%)  
 Biopsy 9 (5.8%) 6 (12.0%)  
 No data 13 1  
First-line therapy    
 Radiotherapy alone 28 (16.6%) 7 (13.7%) 0.927 
 Radiotherapy plus TMZ 134 (79.3%) 43 (84.3%)  
 Radiotherapy plus others1 2 (1.2%) 0 (0%)  
 Radiotherapy plus TMZ plus 
 others1 
5 (3.0%) 1 (2.0%)  
PFS-1 (months)    
 Median (95% CI) 8.7 (6.3-11.3) 6.9 (5.3-8.5) <0.001 
Karnofsky performance 
score at recurrence 
   
 90-100 42 (34.4%) 13 (34.2%) 0.014 
 70-80 65 (53.3%) 13 (34.2%)  
 <70 15 (12.3%) 12 (31.6%)  
Not available 47 13  
Surgery at first recurrence 71/169 (42.0%) 8/51 (15.7%)  
 Gross total resection  34 (56.7%)  2 (28.6%) 0.254 
 Subtotal resection (50-99%)  22 (36.7%)  5 (71.4 %)  
 Partial resection (<50%)  4 (6.7%)  0 (0.0%)  
 Extent of resection unknown  11  1   
MGMT promoter 
methylation status 
   
 Methylated 88 (52.1%) 11 (21.6%) <0.001 
 Unmethylated 81 (47.9%) 40 (78.4%)  
1Tumor-treating fields, cilengitide, temsirolimus, galunisertib, proton beam therapy, 
gene therapy
 
Table S2: Details on therapeutic regimens at second or later recurrence 









- patients without any systemic 
therapy for second or later 
recurrence  
- patients with at least 1 further line 
of salvage therapy 
Bevacizumab/ 
bevacizumab-





































- plus irinotecan 



















n=213 n=31 n=354  
Temozolomide n=6 n=28 n=4  
Hydroxyurea + Imatinib  n=8   
Temsirolimus n=3    
Irinotecan  n=1   
Etoposide   n=1 n=1 
Hydroxyurea  n=1   
Imatinib  n=2   
Trophosphamide + etoposide  n=1   
APG101   n=1  
Ifosfamide + carboplatin + 
etoposide 
n=2    
Carboplatin n=1  n=1  
Carboplatin + etoposide    n=1 
Parvovirus-based therapy n=1    
BGJ398   n=1  
Everolimus   n=1  
Erlotinib + Sirolimus  n=1   
Teniposide  n=1   
Cilengitide   n=1  
Nivolumab n=1    
Radioimmunotherapy (not 
otherwise specified) 
 n=1   
Re-irradiation applied as salvage 
therapy at any further recurrence 
14 22 4 1 
1One patient received bevacizumab monotherapy followed by bevacizumab in combination with irinotecan 
2This group includes regimens with nitrosoureas alone as well as nitrosoureas in combination with various other chemotherapies 
(procarbazine, procarbazine+vincristine, teniposide, irinotecan, etoposide, enzastaurin, cytarabin) 
3One of these patients with a nitrosourea-based regimen received bevacizumab in combination with nitrosoureas 
4This group also includes patients with continuation of bevacizumab used in combination with a nitrosourea-based regimen for second 
or later recurrence 
 
Table S3: Outcome stratified for further salvage therapies 
 All patients 
n=344 
Patient cohort with known IDH status and exclusion of 
patients with IDH-mutant-tumors 
n=220 
Therapy at first 
recurrence 
Alkylating agents, n=260 Bevacizumab, n=84 Alkylating agents, n=169 Bevacizumab, n=51 
Salvage therapy 































































Table S4: Multivariate analysis for survival after first recurrence in the 
subgroup of patients with known IDH status and exclusion of patients with IDH-
mutant-tumors 
 
Model Factor HR 95% CI p value 
1 
(n=206) 
Therapy at recurrence: 
Alkylating agents versus bevacizumab 
(ref) 
0.57 0.39-0.83 0.003 
 MGMT: 
Methylated versus unmethylated (ref) 
0.86 0.62-1.18 0.339 
 Age (years) 
≤65 versus >65 (ref) 
0.81 0.56-1.17 0.264 
 Firstline therapy 
Radiotherapy plus TMZ +/- others versus 
radiotherapy +/- others (ref) 
0.87 0.56-1.33 0.504 
 Extent of initial surgery: 
Gross total versus no total (ref) 
0.80 0.60-1.07 0.132 
     
2 
(n=206) 
Therapy at recurrence: 
Alkylating agents  bevacizumab 
versus 
Bevacizumab  alkylating agents (ref) 
 
Alkylating agents  no bevacizumab 
versus 
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Alkylating agents & MGMT unmethylated
(n=81)
Alkylating agents & MGMT methylated
(n=88)
Bevacizumab & MGMT unmethylated
(n=40)

































Alkylating agents & MGMT unmethylated
(n=122)
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(n=138)
Bevacizumab & MGMT unmethylated
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Alkylating agents & MGMT unmethylated
(n=122)
Alkylating agents & MGMT methylated
(n=138)
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(n=64)
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(n=20)
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Alkylating agents -> bevacizumab
(n=46)
Bevacizumab -> alkylating agents
(n=26)
Alkylating agents -> no bevacizumab
(n=123)





























Alkylating agents -> bevacizumab
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Subgroup with all patients receiving
systemic salvage therapy for second relapse
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